Axsome's Auvelity Surpasses Sales Expectations, Alzheimer's Expansion Holds Key to Future Growth
Axsome Therapeutics' preliminary 2025 results reveal blockbuster-level sales for its depression drug Auvelity, while investor focus intensifies on its potential FDA label expansion for Alzheimer's disease agitation—a move that could redefine the company's valuation and pipeline prospects.